Cognition Therapeutics
Latest round
- Series B
Last raised
- Sep 2015
Total raised
- $16M
Investors
- 15
About Cognition Therapeutics
operates as a developer of drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. In September 2022, Cognition Therapeutics, Inc. Cognition Therapeutics, Inc. specializes in the development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company’s product CT1812, which is a an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. It focuses on neurodegenerative and neuro-ophthalmic diseases that are caused by the age-related buildup of pathogenic proteins such as amyloid beta (Aß) and alpha-synuclein as well as other stressors such as reactive oxygen species (ROS).
Who invested in Cognition Therapeutics
15 investors across 3 rounds
See all investors in Cognition Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cognition Therapeutics
Who invested in Cognition Therapeutics?
Cognition Therapeutics has 15 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cognition Therapeutics raised?
Cognition Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cognition Therapeutics last raise money?
Cognition Therapeutics's most recent round on record is a Series B, in Sep 2015.
What does Cognition Therapeutics do?
operates as a developer of drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders.
Where is Cognition Therapeutics headquartered?
Cognition Therapeutics is headquartered in Purchase, US.
Which VCs invest in companies like Cognition Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cognition Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Cognition Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.